BioNTech announced all-stock acquisition of CureVac in public exchange offer, ~$5.46 per CureVac share in BioNTech ADSs, total implied equity value ~$1.25B. Strengthens BioNTech's mRNA oncology platform and resolves prior patent litigation. Closed December 18, 2025. BioNTech completed the post-offer compulsory acquisition of the residual minority shares in January 2026, taking CureVac to 100% ownership and ending its public listing.
Key facts
AnnouncedJun 12, 2025
ClosedDec 18, 2025
Deal value$1.2B
Deal typeAcquisition/Merger
Therapeutic areaOncology
IndicationsOncology
Key assetsmRNA-based cancer immunotherapy pipeline